Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: John Chatterton who wrote (7462)	4/19/1999 11:15:00 PM
From: BigKNY3	Read Replies (3) \| Respond to of 9523

John Chatterton <<Muse is awkward to use. It's uncomfortable. It's less effective. And it's more expensive.Viagra is easy to use. For most people, it has no ill effects. For most, it works. And it's relatively cheap. >> John: The marketplace has also spoken. 98% of all non-injectable prescriptions for ED are currently written by physicians for Viagra. This stat has not changed since 4/24/98. Viagra currently has no competition until Vasomax and ICOS' PDE5 product arrive. The most important factor for the future growth of Viagra is seeking out those ED patients who still have not sought out treatment. Approximately 4 million patients have now been prescribed Viagra in the US...probably the largest patient base for a pharmaceutical in its first year. However, this represents only 20% or less of the total potential ED patients (20 million+). Within 5 years, Viagra will probably sell $2-$3 billion a year. With patent protection until 2011, every single pharmaceutical company would love to have Viagra in its portfolio. BigKNY3